Clinical Benefit Seen With In-Hospital Initiation of Empagliflozin in Heart Failure Patients
Findings showed that patients treated with empagliflozin were 36% more likely to experience a clinical benefit.
Diagnosis & Disease Information
Mavacamten Evaluated in Patients With Obstructive Hypertrophic Cardiomyopathy Eligible for SRT
The VALOR-HCM trial evaluated the effects of mavacamten in over 100 patients with symptomatic obstructive HCM (NYHA class III-IV) who met the guideline criteria for SRT and had been referred for an invasive procedure.
MPR Weekly Dose Podcast Episode 107
This week: millions of courses of a COVID-19 oral antiviral was provided to the US government for distribution throughout the country; There’s a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF.
Omecamtiv Mecarbil Under Review for Heart Failure With Reduced Ejection Fraction
The NDA is supported by data from the phase 3 GALACTIC-HF trial which included 8256 adults with heart failure with reduced ejection fraction,
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
SGLT2 Inhibitor Use May Benefit Patients With HFpEF
SGLT2 inhibitor use may reduce the risk for CV death or hospitalization for heart failure in HF patients with preserved ejection fraction
Aficamten Gets Breakthrough Tx Status for Obstructive Hypertrophic Cardiomyopathy
The designation was based on data from the phase 2 REDWOOD-HCM trial.
Aspirin Use Tied to Incident Heart Failure in At-Risk Adults
Aspirin use associated with increased risk for incident heart failure among individuals with or without a history of cardiovascular disease
Polypharmacy May Increase Risks for Kidney Failure, Cardiovascular Events
Avoiding unnecessary medications in CKD might reduce the risks for adverse outcomes, investigators suggested.
Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
